Introductory paragraph.
The current understanding of tumorigenesis is largely centered on a monogenic driver oncogene model. This paradigm is incompatible with the prevailing clinical experience in most solid malignancies: monotherapy with a drug directed against an individual oncogenic driver typically results in incomplete clinical responses and eventual tumor progression [1] [2] [3] [4] [5] [6] [7] . By profiling the somatic genetic alterations present in over 2,000 cases of lung cancer, the leading cause of cancer mortality worldwide 8, 9 , we show that combinations of functional genetic alterations, i.e. genetic collectives dominate the landscape of advanced-stage disease. We highlight this polygenic landscape and evolution of advanced-stage non-small cell lung cancer (NSCLC) through the spatial-temporal genomic profiling of 7 distinct tumor biopsy specimens and 6 plasma specimens obtained from an EGFR-mutant NSCLC patient at (1) initial diagnosis of early-stage disease, (2) metastatic progression, (3) sequential treatment and resistance to 2 EGFR inhibitors, (4) catenin and PI3K pathway genes, which our data suggest can cooperatively impart non-redundant functions to limit EGFR targeted therapy response and/or promote tumor progression. Moreover, evidence of an unanticipated parallel evolution of both EGFR T790M and two distinct forms of oncogenic PIK3CA was observed.
Our study provides a large-scale clinical and genetic dataset of advanced-stage EGFR-mutant NSCLC, a rationale for specific polytherapy strategies such as EGFR and CDK4/6 inhibitor co-treatment to potentially enhance clinical outcomes, and prompts a re-evaluation of the prevailing paradigm of monogenic-based molecular stratification for targeted therapy. Instead, our findings highlight an alternative model of genetic collectives that operate through epistasis to drive lung cancer progression and therapy resistance.
Main text.
The identification of specific, therapeutically targetable genetic alterations that drive the growth of many cancers including non-small cell lung cancer (NSCLC), the major subtype of lung cancer, has revolutionized the diagnosis and treatment of patients. The clinical success of genetically-targeted therapies such as EGFR, ALK, ROS-1 and BRAF inhibitors [1] [2] [3] [4] [5] [6] [7] 10, 11 has led to the current monogenic driver oncogene model of tumorigenesis, wherein advanced-stage NSCLC patients are selected for a gene-targeted monotherapy based on the identification of an individual specific driver alteration present in the tumor (e.g. mutant EGFR or an ALK gene rearrangement). This model is incompatible with the prevailing clinical experience in most advancedstage solid malignancies including NSCLC, wherein monotherapy with a drug directed against a particular oncogenic driver protein, while typically more effective than cytotoxic chemotherapy, generally results in incomplete responses and eventual tumor progression in patients (reviewed in 12 ). In contrast to this monogenic model of disease pathogenesis and treatment, it is possible that advanced-stage NSCLCs exhibit a polygenic landscape of functional gene variants that cooperate to limit response to treatment and/or promote tumor progression, potentially in conjunction with other events (e.g. secreted factors and/or stromal cells). In support of this hypothesis, recent important studies have revealed intra-tumor heterogeneity and co-occurrence of gene alterations in small NSCLC cohorts [13] [14] [15] [16] [17] . However, these prior reports were limited by either the small clinical cohort size and lack of associated clinical and treatment outcome data, the number of genes analyzed, and/or were focused on early-stage (e.g. TCGA lung adenocarcinoma project) rather than advanced-stage NSCLC, the latter comprising the patient population which is treated with systemic targeted therapy and therefore of paramount relevance. On this basis, we set out to address a critical unresolved question in the field: to what extent are advanced-stage NSCLCs comprised of combinations of functional somatic genetic alterations (genetic collectives) that could operate through genetic epistasis to cooperatively influence tumor progression and clinical outcomes? Critical to addressing this question was our ability: (1) to assemble a substantial cohort of clinical samples linked to clinical outcome and treatment response data, many through longitudinal specimen collection in individual patients, and (2) to characterize the somatic genetic alterations present within these cancers by whole exome sequencing and/or cfDNA profiling and link the genetic findings to clinical outcomes.
To test the hypothesis that a polygenic landscape of functional gene variants can cooperate to limit response to treatment and/or promote tumor progression through genetic epistasis in advanced-stage lung cancer, we first obtained a unique series of EGFR-mutant NSCLC clinical specimens from an individual patient and profiled them by both tumor-based whole exome sequencing and cfDNA analysis. EGFR-mutant NSCLC represents a specific NSCLC subtype (typically comprising 10-20% of cases) that is defined by the presence of an oncogenic mutation in EGFR that identifies patients who are likely to respond to an approved EGFR inhibitor (erlotinib, gefitinib, afatinib, osimertinib). These specimens were obtained over the course of 6 years from a patient who was initially diagnosed with surgically resectable disease in 2009, then suffered local progression in the mediastinum and distant metastatic progression in the lungs, bone, and brain over the ensuing 6 years. This disease course included an incomplete response and then progression first upon treatment with the first-generation EGFR inhibitor erlotinib and then upon treatment with the third-generation EGFR inhibitor rociletinib 3 ( Fig. S1 ). Seven tumor (4 lung, 2 bone, and 1 lymph node) and six plasma specimens were analyzed longitudinally during this disease progression to identify somatic genetic alterations, including 4 specimens obtained at autopsy upon lethal tumor progression on rociletinib.
The whole exome sequencing analysis of the tumor samples showed multiple concurrent functionallyrelevant somatic alterations present at the initial diagnosis of early-stage disease (R1), including clonal and truncal EGFR exon19del , CTNNB1 S37F 18 , SMAD4 L146X , and RBM10 S167X mutations and CDK2NA copy number loss (Fig. 1a-b, S2, S3, Tables S1-S2 ). Progression to mediastinal lymph node metastasis (R2) was marked by acquisition of mutations in PRKCA(N468I) 19 and PIK3CA(G106V) 20 , in addition to copy number gain (CNG) in the genomic region encoding EGFR, CDK6, MET, and BRAF (Fig. 1a-c, S2 , Tables S1, S3 ). Progression on erlotinib therapy occurred upon acquisition of the EGFR T790M mutation, as found in ~60% of EGFR-mutant NSCLC patients who progress on first-generation EGFR inhibitor treatment 21 , and the persistent presence of additional genetic events including CTNNB1 S37F and PIK3CA G106V . Our data suggest that the PIK3CA G106V mutation arose prior to EGFR inhibitor treatment and also prior to acquisition of the EGFR T790M mutation (Fig.   1a) . Interestingly, the EGFR T790M mutation may have arisen in this case through a previously unreported instance of independent dual clonal origins. Given that the EGFR T790M mutation was found in metastatic sites that harbored PIK3CA G106V (R3-left lung at erlotinib progression, R4-left lung at rociletinib progression, and R6-right lung at rociletinib progression) and those that did not (R5-right rib metastasis and R7-spine metastasis), the data suggest that the EGFR T790M mutation arose in parallel sites independently (Fig. 1a-c, S3 ). Further progression on rociletinib was associated with the emergence of additional subclonal genetic co-alterations, including PIK3CA H1047R (R5-right rib), RB1 R857H (R4-left lung), CHD4 H1151P (R6-right lung) and TLR4 R289Q (R5-right rib) (Fig. 1a-c) . The activating PIK3CA G106V mutation 20 was not found in all of the post-rociletinib metastatic sites (present in R4, R6; absent in R5, R7), demonstrating lesion-specific metastatic heterogeneity ( Fig. 1a-b ). Intriguingly, a subclonal PIK3CA H1047R 22 oncogenic mutation was found in R5 (right rib, postrociletinib), suggesting another parallel evolution of two different PIK3CA oncogenic mutations in this patient's cancer ( Fig. 1a-c, S3 ). Although an RB1 somatic mutation (R847H) was detected in R4 (left lung-at rociletinib progression) and RB1 inactivation has previously been associated with a transition from lung adenocarcinoma to small cell carcinoma in the setting of EGFR inhibitor resistance 23, 24 , there was no evidence of histological transformation to small cell carcinoma in these clinical specimens perhaps due to the lack of a somatic TP53 genetic alteration in this case (Fig. S4 ). While plasma samples for cfDNA analysis were not available for all initial clinical events (i.e. diagnosis and metastatic progression prior to erlotinib treatment), the coupling of the tumor biopsy and cfDNA exome data (Methods) in this patient revealed examples of ubiquitous (e.g.
EGFR ex19del
, CTNNB1 S37F ) and more lesion-restricted (PIK3CA
G106V
, RB1 R857H , and TLR4 R289Q ) mutations in the plasma (Fig. 1d ). This finding suggests that the cfDNA analysis integrates multiple metastatic tumor lesions.
The whole exome-based analysis of this cancer revealed a profound spatial-temporal evolution of the tumor and the presence of multiple oncogenic and tumor suppressor gene alterations that could contribute to tumor progression, incomplete EGFR inhibitor response (i.e. disease persistence), and resistance to EGFR inhibitor treatment, even beyond the EGFR T790M mutation alone. The data indicated that the truncal mutations accounted for over 75% of the coding mutational burden at diagnosis but only 50-58% of the coding mutational burden at the time of full cancer evolution (patient death) in this case, with the emergence of subclonal mutations through tumor progression and both first-and second-line EGFR inhibitor resistance (Fig 1a) .
Overall, the findings in this case suggest an unanticipated parallel evolution of both the EGFR T790M mutation and two different PIK3CA driver alterations and are consistent with a genetic epistasis model in which the cooccurrence and co-evolution of several oncogene and tumor suppressor co-alterations present in the cancer influenced tumor progression and clinical outcome.
The oncogenic alleles of both CTNNB1 (β-catenin) and PIK3CA (G106V) were of particular functional interest in the genetic evolution of this cancer and we set out to define their potential roles, individually and in concert in the context of EGFR-mutant NSCLC. Oncogenic activation of CTNNB1 has not been linked functionally to tumor progression or incomplete EGFR inhibitor response in EGFR-mutant NSCLC patients, while PIK3CA G106V has not previously been shown to impact NSCLC progression or EGFR inhibitor response.
PIK3CA
H1047R has been linked to lung cancer progression 22 and promotes an invasive and metastatic phenotype when expressed in mammary epithelial cells 25 . The fact that PIK3CA H1047R was found at a metastatic site (R5) that did not harbor the PIK3CA G106V mutation (Fig. 1a-c) suggests that tumor metastasis is at least partially dependent on PI3K pathway activation. Functional analysis of CTNNB1 nuclear expression and the levels of phosphorylated AKT (as a measure of β-catenin and PI3K signaling activation, respectively) in the patient's tumor samples confirmed activation of each pathway particularly in specimens with these activating alterations in CTNNB1 and PIK3CA (Fig. S4) 26 , and also contributes to incomplete EGFR inhibitor response.
G106V was not identified in the primary tumor, but only emerged upon lymph node metastases and then persisted during both EGFR inhibitor treatments (Fig. 1a-b 28 suggests that it may play a role in epigenetic regulation of gene expression in this cancer, which has been linked previously with EGFR inhibitor tolerance 29 . The TLR4 R289Q mutation we detected is predicted (Mutation Assessor;cbioportal.org) to impact function and may be an activating variant 30 linked to NF-κB activity, which we have shown can promote EGFR inhibitor resistance 31, 32 . Future studies beyond the scope here will be required to assess the functions of these additional genetic alterations.
These data highlighted the possibility that tumor progression and EGFR inhibitor response may be (Fig. 2b, S8 ). Enrichment for the EGFR T790M mutation was found upon progression on first-line EGFR inhibitor treatment (56.5% vs. 0%, p = 1.0E-5), as expected based upon the rare detection (~0.5%) of EGFR T790M prior to first-generation EGFR inhibitor treatment 35 and the established incidence of EGFR T790M (55%-65%) upon progression on first-generation EGFR inhibitors 21 ( Fig. 2a ,b, Table S6 ). Upon progression on second-line treatment (EGFR inhibitor or chemotherapy), the analysis revealed further selection for co-alterations in CCNE1 (18% vs. 2.1%, p = 0.03), and KIT (13.6% vs. 0%, p = 0.03), with trends towards increases in alterations in MYC (18% vs. 4%, p = 0.08), PIK3CA (23% vs. 8.6 %, p = 0.14), and CTNNB1 (18% vs. 10%, p = 0.11) (Fig. 2c) . Alterations in genes involved in receptor tyrosine kinase (RTK), MAPK, Cell Cycle, PI3K, and WNT signaling were more frequently found in patients who had progressed on 2 nd line therapy ( Fig. 2d and Table S6 ). The mean number of functional alterations detected in cfDNA was lower in patients who responded to subsequent EGFR inhibitor therapy versus those who did not respond to this subsequent treatment (2.3 vs. 3.9, p=0.0005, Fig. S9 , To provide further support for this genetic epistasis model, we undertook a large-scale analysis using the clinically-validated cfDNA assay (Table S4, (Table S9) , of which a subset was analyzed above ( Fig. 2 and 3 ).
To enhance focus on the most functionally relevant genetic alterations, we filtered for mutations that were nonsynonymous and validated or predicted to impact gene function (Methods), which yielded 1150 EGFRmutation-positive and 945 EGFR mutation-negative cases. While clinical outcomes data are not readily available for most patients represented in this larger sample set, this cfDNA cohort contains advanced-stage NSCLC patients who are often heavily pre-treated and as such it differs from TCGA and other genomic compendia of lung cancer that are based largely on the analysis of early-stage resected tumors in patients who generally are not as exposed to systemic drugs such as EGFR inhibitors. Therefore, this cfDNA cohort represents the landscape of resistance and the initial driver/founder mutations. Analysis of the 1150 EGFRmutant patient cohort revealed the widespread presence of concurrent genetic alterations, in addition to the EGFR driver mutation (Fig. 4a) . Overall, the vast majority of patients (93.1%; 1071 out of 1150) harbored at least one additional variant of known or likely functional significance (Table S10 ). The EGFR-mutant cases contained an average of 3.6 genetic alterations (out of the <70 genes profiled), including the EGFR mutation that was present (range 1-18). There was enrichment for co-alterations in CTNNB1 (5.3% vs. 1.8%, p = 2.2E -05 ), CDK6 (6.9% vs. 3.2%, p = 1.5E -04 ), AR (5.0% vs. 2.6%, p = 0.007), and a modest difference in TP53 (55% vs. 50%, p = 0.04) in the EGFR-mutant cohort, compared to the stage-matched EGFR mutation-negative cohort similarly profiled using the cfDNA assay (n=945) (Fig. 4a-b , S11, S12, Table S10, S11). The pathwaylevel analysis showed selection for genetic co-alterations in WNT/CTNNB1 and hormone signaling genes in the EGFR-mutant cohort, whereas alterations in several functional groups including RTKs and MAPK pathway genes (e.g. KRAS) were more enriched in the EGFR mutation-negative cohort (as expected) (Fig. 4c and S11 ).
This large-scale dataset further suggests an important role for WNT/CTNNB1 signaling, consistent with a small case series 24 , and cell cycle gene aberrations in the pathogenesis of EGFR-mutant NSCLC, re-enforcing our earlier findings linking alterations in these genes and pathways to clinical outcomes and treatment response in EGFR-mutant NSCLC patients ( Fig. 1-3 35 . Analysis of the genetic co-alterations present in the 450 EGFR T790M -positive cancers revealed more frequent alterations in certain pathways compared with the EGFR T790M -negative cases (n=700) (Fig. 4d -e, S13, Table S12 and S13). This specific enrichment included co-alterations in genes and pathways controlling the cell cycle (CDK6 and CCNE1 CNGs),
WNT signaling (CTNNB1 oncogenic mutations), hormone signaling (androgen receptor, AR, somatic mutations), epigenetic modification (MYC CNG), KRAS and PDGFRA gene alterations (CNG and oncogenic mutations), as well as BRCA1 mutations being more common in the EGFR T790M -positive cases (Fig. 4d , S14, S15). In a sub-analysis of EGFR C797S mutation-positive cases (n=15), which are predicted to arise upon acquired resistance to osimertinib 38 , recurrent activating alterations in MAPK pathway (including KRAS CNG and oncogenic mutations) and cell cycle genes (CDK4, CDK6), and AR CNGs were identified (Fig. S16 ).
These data further suggest that multiple co-alterations in specific genes and pathways controlling cancer growth, likely in cooperative or non-redundant ways may contribute to incomplete EGFR inhibitor response and resistance, even in cancers with EGFR T790M and EGFR C797S . This finding of polygenic oncogenic alterations in the larger cohort of EGFR T790M -positive patients is consistent with our earlier clinical data linking several of these genes and pathways to clinical outcomes and treatment response in EGFR-mutant NSCLC patients ( Fig.   1-3) . Together, these data in EGFR T790M -positive cases offer insight into the potential basis of the typically incomplete clinical responses to EGFR T790M -directed therapies such as osimertinib in EGFR T790M -positive NSCLC patients and identify potential combination therapy strategies to enhance response.
By extension of our initial tumor biopsy exome analysis (Fig. 1) , we assessed whether these genetic coalterations detected in the cfDNA were clonal versus subclonal in EGFR-mutant NSCLC. A method for assessing clonality in tumor cfDNA has not been established, in contrast to the analysis of tumor samples by exome deep sequencing. Our strategy was to compare the mutant allele frequency (MAF) for an altered gene to the maximum MAF detected in a given sample. To estimate the relative proportions of cfDNA that would differentiate a mutant allele as clonal versus subclonal, as a benchmark we correlated the tumor-based clonality analysis in Fig. 1a with the cfDNA mutational analysis from the same patient upon progression on rociletinib (Fig. 1c) . The CTNNB1 S37F mutation was clonal in the patient tumors at autopsy (Fig. 1a and S3,   S4 ), but present at only 50% of the maximum mutant allele (EGFR ex19del ) detected in the cfDNA (Fig. 1c) . In contrast, the PIK3CA G106V mutation was subclonal (only present in 2 of 4 metastatic sites) at autopsy (Fig. 1a,b and S3) and correspondingly present at only 5% of the maximum MAF in the cfDNA (Fig. 1d) . Based on this analysis, we estimated that clonal alterations may be detectable as low as 20% of the maximum MAF in ctDNA, but likely to be subclonal when detected at < 20%. Using this approach, we found that EGFR mutation-positive NSCLCs are more likely to harbor subclonal genetic alterations than EGFR mutationnegative NSCLCs (Tables S10, S11 26.6% subclonal events in EGFR-mutation negative cases, p = 1.759e -9 ). Subclonal alterations were also more commonly found in tumors that harbored EGFR T790M (Tables S12, S13 These observations are consistent with our earlier findings ( Fig. 1-3 ) in support of a genetic epistasis model wherein both clonal and subclonal evolution of several oncogene and tumor suppressor co-alterations, beyond EGFR mutations alone, may influence EGFR-mutant NSCLC progression and drug response. Overall, the data uncover a previously underappreciated degree of selection for specific genetic co-alterations in cancer-relevant genes within advanced-stage EGFR-mutant NSCLCs, providing evidence that the pathogenesis of this subtype of NSCLC may be polygenic and not merely monogenic (i.e. controlled by mutant EGFR alone).
The uncommon opportunity to longitudinally capture multiple tumor biopsies from an individual patient over several years: from the time of the initial diagnosis of early-stage disease, to metastatic progression, to NSCLC that we uncover here, paving the way for additional potential polytherapy trials to enhance the magnitude and duration of response in patients.
Our findings prompt a re-consideration of advanced-stage EGFR-mutant NSCLC as largely a polygenic rather than monogenic disease, thus re-shaping the understanding of the basis of NSCLC established by earlier important genomic studies that focused predominantly on early-stage lung cancer (e.g. TCGA) in patients not receiving systemic targeted therapy. Our data highlight the importance of deploying more informed molecular diagnosis, monitoring, and dynamically-applied rational polytherapy strategies to address the genetic epistasis of clonal and subclonal alterations that our data reveal in order to better control this deadly cancer. Table S5 ) with line of therapy. (b and c) Two-way Fisher's exact test was performed to identify statistically significant differences between pre-TKI and PD to 1 st line, between PD to 1 st line and PD to 2 nd line, and between pre-TKI and PD to 2 nd line. Methods.
Whole-exome sequencing and analysis:
Informed consent was obtained from the patient and patient's family for study of biological materials and clinical records obtained from the patient. DNA was extracted from FFPE for primary tumor and frozen tumor tissue samples and matched non-tumor tissue using the Qiagen Allprep DNA/RNA Mini Kit. The library preparation protocol was based on the Agilent SureSelect Library Prep and Capture System (Agilent Technologies, Santa Clara, CA). Quantitation and quality were assessed using the Qubit Flourometer (Thermo Fisher). DNA concentration was determined to be greater than 2.5 ng/ul and the overall quantity > 500ng. By Nanodrop, the 260/280 ratio was greater than 1.7. DNA was resuspended in a low TE buffer and sheared (Duty Cycle 5%; Intensity 175; Cycles/Burst: 200; Time: 300s, Corvaris S2 Utrasonicator). Bar-coded exome libraries were prepared using the Agilent Sure Select V5 library kit per manfucaturer's specifications. The libraries were run on the HiSeq2500.
Alignment
Raw paired end reads (100bp) in FastQ format generated by the Illumina pipeline were aligned to the full hg19 genomic assembly obtained from USCS, gencode 14, using bwa version 0. 
Classification of SCNAs
SCNA events were defined as segments called by ASCAT >= 400kb in size that met set thresholds. Segments with a combined raw nMinor and nMajor greater than a 1.5 times the ASCAT derived ploidy for their specific tumor region were considered SCNA gains. SCNA losses had an integer nMinor value of 0 and a combined raw nMinor and nMajor of less than 1.25 times ploidy for their specific tumor region.
Incorporation of T790M mutation into phylogenetic reconstruction
In order to create and accurate subclonal phylogeny it is necessary to remove mutation clusters that violate two evolutionary principles. Firstly the pigeonhole principle which ensures that two mutation clusters cannot be considered to be on separate branches of an evolutionary tree and thus be independent if the cancer cell fraction values of the two clusters together exceeds 100% within region of a tumor. Secondly, a descendent clone must have a smaller cancer cell fraction than its ancestor within each and every tumor region, referred to as the 'crossing rule'. Using these principles it can be determined whether particular mutation clusters conflict with each other and cannot be fitted to the same evolutionary tree.
The subclonal phylogeny illustrating the entire course of the patient's disease was derived following these two principles and the methods of multi-sample subclonal deconstruction and tree construction in [Jamal- No other SNV appears clonal in all these regions as well as being absent from both R1 and R2. As cluster 7 and the EGFR T790M mutation appear clonal in R3, R4, and R6 but cluster 7 is absent from R5 and R7 and EGFR T790M is present they cannot, by the crossing rule, be present in the same population of cells. In addition, as cluster 7 was present clonally in R2 before Erlotinib treatment while T790M is absent from R2, it follows that cluster 7 is likely to have arisen before the T790M SNV.
The most parsimonious solution to this violation of the crossing rule, assuming that the cancer cell fractions are correct, is that there are two independent origins of T790M. T790M SNV (A) would occur in a cell already containing the SNVs from cluster 7, and go on to become clonal post-Erlotinib treatment in R3, R4 and R6.
T790M SNV (B) would occur in a population of cells lacking the SNVs present in cluster 7 and go on to become clonal in R5 and R7 post-Erlotinib. These possible origins of the T790M are indicated on the subclonal phylogeny that can be seen in Figure X by the placement of a magenta square on the relevant branches.
Data Availability
All exome sequencing data will be available through the European Genome-phenome Archive (EGA), accession number: Pending.
Code availability
Most bioinformatics tools used in the analysis of this dataset are publicly available; any that are not are available on request. 33, 43 . All cell-free DNA fragments, both leukocyte-and tumor-derived, were simultaneously sequenced. The variant allele fraction (VAF) was calculated as the proportion of cfDNA harboring the variant in a background of wild-type cell-free DNA. The analytic sensitivity reaches detection of 1-2 mutant fragments in a 10 ml blood sample (0.1% limit of detection) with analytic specificity > 99.9999% 33, 43 . CNGs were reported as the absolute gene copy number in plasma. For longitudinal case (Fig. 4d) , cell-free DNA was isolated from 1 ml of frozen plasma and analyzed as described 17, 44 . Clinical data was collected by review of medical records under an IRB-approved protocol (UCSF). Non-synonymous mutations from EGFR-mutant positive and negative datasets were further processed using R statistical computing program (version 3.3). Unknown significant variants were filtered out by using COSMIC (V79), GENIE(http://www.aacr.org/Research/Research/Pages/aacr-projectgenie.aspx#.WMeBiRLytaM) and prediction algorithm (http://mutationassessor.org/r3/). For clonality analysis, the ratio of MAF over Maximum-percentage detection (Max-pct) were computed, the probability distribution was plotted using kernel density estimation. 46 ; pCMV-VSV-G (Addgene plasmid # 8454) and pUMVC (Addgene plasmid # 8449) 47 were a gift from Bob Weinberg; pBabe puro HA PIK3CA was a gift from Jean Zhao (Addgene plasmid # 12522) 48 ; human betacatenin pcDNA3 was a gift from Eric Fearon (Addgene plasmid # 16828) 49 . The PIK3CA and b-catenin constructs were engineered to express G106V PIK3CA and S37F CTNNB1 following QuickChange II XL SiteDirected Mutagenesis Kit protocol (Agilent Technologies). The S37F CTNNB1 fragment was then sub-cloned in a pQCXIB retroviral construct for stable overexpression, using sticky ends ligation with ApaI and BamHI-HF (New England BioLabs) restriction enzymes, per manufacturer's instructions. HEK293-FT cells were transfected with pBABE (empty vector), pBABE-G106V PIK3CA, pQCXIB (empty vector) and pQCXIB -S37F CTNNB1 using Fugene 6 (Promega) per manufacturer's instructions. Virus containing media was harvested at 24 hrs and 48 hrs post-transfection. HCC827 cells were infected with virus containing media, supplemented with 8 µg/ml of polybrene (Sigma-Aldrich), for 24 hours. The culture medium was changed to standard growth media for an over-night incubation, after which cells were incubated in antibiotic selecting medium containing puromycin 1 ug/mL (Gibco) for p-Babe construct or blasticidin 2.5 ug/mL (Gibco) for pQCXIB constructs.
Cell
Antibiotic resistant cells were used in the subsequent tests.
Cell Viability and Growth Assays: One hundred thousand of HCC827 cells, engineered with the S37F b-catenin and G106V PIK3CA constructs, and under puromycin (1 ug/mL) and blasticidin (2.5 ug/mL) selection, were seeded in 12 well plates and, after 24 hrs, treated with DMSO (control), erlotinib (50-100 nM) and rociletinib (100 nM), in 2% FBS, for three days. Cells were then air-dried for 5 minutes, fixed for 5 miutes in ParaFormAldehyde (PFA, 4% vol/vol; Santa Cruz Biothechnology) and stained in 0.05% crystal violet (g/mL;
Sigma-Aldrich) solution for 30 minutes. Each well was washed twice with tap water and air-dried. Plates were scanned using ImageQuant LAS4000 (GE Healthcare Life Sciences). Each image is representative of a triplicate experiment. Cell viability was assessed using the above culture conditions, seeding two hundred of cells each well. Cell count was registered after three days of growth and assessed using Vi-CELL XR. Each test was run in triplicate. One-way ANOVA and Student's T-test with Bonferroni correction were used to assess statistical significance (GraphPad Prism). The variation between the sample sets was similar and expressed as standard deviation.
Invasion and Migration Assays:
Transwell migration and invasion assays were performed as described in
Okimoto et al. 50 Briefly Immunoblotting and q-RT-PCR. The HCC827 cells engineered with the S37F b-catenin and G106V PIK3CA constructs were drug treated, in serum free condition, with DMSO (control), erlotinib (100 nM) and rociletinib (100 nM) for 24 hrs. Protein lysates were collected in RIPA buffer supplemented with protease (Roche) and phosphatase (Roche) inhibitors. Western blot was performed loading 10 ug of lysed proteins. Pre-casted 4-15% gels (Bio-Rad) were used for the mono-dimension protein separation. Proteins were transferred on nitrocellulose membranes using Trans-blot Turbo Transfer system (Bio-Rad). Blots were then blocked in Trisbuffered saline, 0.1% Tween20 (vol/vol) and 5% BSA (Fischer Scientific, vol/vol) for 1 hr, at room temperature.
The primary antibodies were incubated over-night, at 4ºC. The primary antibodies used were: pY1068-EGFR D7A5 (#3777), total EGFR D38B1 (#4267), β-Catenin D10A8 (#8480), pS473-AKT D9E (#4060), total AKT (#9272), pT202/Y204-ERK1/2 (#9101), total ERK1/2 (#9102) and cleaved PARP (#9541) from Cell Signaling
Technology; Actin AC-74 (#A2228) from Sigma-Aldrich. The membranes were washed twice in washing buffer (Tris-buffered saline, 0.1% Tween20, vol/vol) and then incubated with secondary HRP conjugated antibodies for 1 hr, at room temperature. ECL kit (GE Healthcare) was used as chemoluminescent substrate. Blots were developed and scanned using ImageQuant LAS4000 (GE Healthcare Life Sciences). ImageJ (NIH) was used to quantify the western blots. All western blots represent the result of three independent experiments.
The RNA was purified from the HCC827 cells engineered with the S37F b-catenin and G106V PIK3CA constructs using RNeasy Micro Kit (Qiagen). One microgram of total RNA was used for the reversetranscriptase reaction with SensiFAST cDNA Synthesis Kit (BIOLINE). The q-PCR was performed with six replicates each condition and using a 1:3 dilution of the template cDNA. Human c-myc, cyclin-D1, LEF-1, HOXB9, and endogenous control GAPDH genes were amplified with Taqman gene expression assay (Applied Biosystems). Gene expression analysis was computed using QuantStudio 12K Flex Software (Applied Biosystems). Data were analyzed using the 2 −ΔΔCt method and expressed as relative mRNA expression. Oneway ANOVA and Student's T-test with Bonferroni correction were used to assess statistical significance (GraphPad Prism). The variation between the sample sets was similar and expressed as standard deviation.
Immunohistochemistry: Immunohistochemistry was performed as described 32 . Briefly, 5-micron thick formalin-fixed paraffin embedded (FFPE) human tissue sections were stained with the β-Catenin D10A8
(#8480 Cell Signaling, 1:100 dilution), or pSer473-Akt D9E (#4060, Cell Signaling, 1:100 dilution) antibody per manufacturer's instructions. Stained slides were digitized using the Aperio ScanScope CS Slide Scanner (Aperio Technologies) with a 20x objective. The proportion of cells exhibiting nuclear β-Catenin staining was determined using the ScanScope default nuclear algorithm. pSer473-Akt quantitation was determined using the ScanScope default membrane algorithm. Three fields of view per section were used to determine the mean and standard error of the mean of positively staining cells.
